Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 5/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4694078 | 0.94 | KDM4E (0.42) | KDM4EPOLBTDP1L3MBTL1SLC2A1 | |
| SCHEMBL4690295 | 0.88 | DHFR (0.37) | SLC2A1DHFRPAX8 | |
| Trifluoroacetic Acid SCHEMBL4691189 | 0.84 | SLC2A1 (0.39) | SLC2A1PAX8ADORA2A | |
| Trifluoroacetic Acid SCHEMBL4693903 | 0.83 | DHFR (0.37) | KDM4EPOLBL3MBTL1DHFRPAX8 | |
| Trifluoroacetic Acid SCHEMBL4706275 | 0.82 | ALDH1A1 (0.36) | KDM4EPOLBTDP1L3MBTL1DHFR | |
| Trifluoroacetic Acid SCHEMBL4710094 | 0.82 | ALDH1A1 (0.36) | KDM4ETDP1L3MBTL1DHFRPAX8 | |
| SCHEMBL4687413 | 0.82 | F2R (0.42) | SLC2A1DHFRADORA2A | |
| Trifluoroacetic Acid SCHEMBL4707306 | 0.82 | NLRP3 (0.36) | KDM4EDHFRALDH1A1ADORA2A | |
| SCHEMBL4689868 | 0.80 | SLC2A1 (0.41) | SLC2A1PAX8ADORA2A | |
| Trifluoroacetic Acid SCHEMBL4707814 | 0.77 | KMT2A (0.37) | KDM4EPOLBTDP1L3MBTL1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, PPP5C, PTP4A2 | KDM4E 296/4885POLB 4097/4885TDP1 276/4885 |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, DUSP15, PPP5C | KDM4E 570/4885POLB 3711/4885TDP1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.